Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan liver disease with no known cure. The Company’s early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company’s antibody discovery technology platform against specified targets. For more information please visit: www.tharimmune.com.
Company profile
Ticker
THAR
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Hillstream BioPharma Inc.
SEC CIK
Corporate docs
Subsidiaries
HB Pharma Corp. • Farrington Therapeutics LLC • On February 27, 2023, the Company ...
IRS number
842642541
THAR stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
22 Mar 24
ARS
2023 FY
Annual report to shareholders
22 Mar 24
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
PRE 14A
Preliminary proxy
11 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
11 Mar 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Other Events
8 Feb 24
8-K
Other Events
12 Dec 23
8-K/A
Other Events
11 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.69 mm | 2.69 mm | 2.69 mm | 2.69 mm | 2.69 mm | 2.69 mm |
Cash burn (monthly) | 404.99 k | 318.46 k | 615.02 k | 724.21 k | 302.99 k | 564.78 k |
Cash used (since last report) | 2.77 mm | 2.18 mm | 4.20 mm | 4.95 mm | 2.07 mm | 3.86 mm |
Cash remaining | -79.81 k | 511.82 k | -1.52 mm | -2.26 mm | 617.57 k | -1.17 mm |
Runway (months of cash) | -0.2 | 1.6 | -2.5 | -3.1 | 2.0 | -2.1 |
Institutional ownership, Q2 2023
13.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 2 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 544.59 mm |
Total shares | 1.54 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Sabby Management | 1.33 mm | $483.44 mm |
Warberg Asset Management | 86.60 k | $31.59 mm |
VIRT Virtu Financial | 45.02 k | $16.00 k |
Geode Capital Management | 37.75 k | $13.77 mm |
STT State Street | 25.77 k | $9.40 mm |
Tower Research Capital | 17.43 k | $6.36 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Dec 23 | Randy Milby | Common Stock | Buy | Acquire P | No | No | 0.503 | 29,000 | 14.59 k | 156,517 |
30 Nov 23 | Randy Milby | Common Stock | Buy | Acquire P | No | No | 1 | 10,000 | 10.00 k | 127,517 |
1 Jan 23 | Randy Milby | Options (right to purchase) Common stock | Grant | Acquire A | No | No | 0.39 | 621,795 | 242.50 k | 621,795 |
1 Jan 23 | Randy Milby | Options (right to purchase) Common stock | Grant | Acquire A | No | No | 0.39 | 515,127 | 200.90 k | 515,127 |
News
Tharimmune Forms Scientific Advisory Board To Drive Clinical-Stage Lead In Chronic Liver Disease And Early-Stage Tunable Knob Domains For Generating Antibody Drug Conjugate Biotherapeutics
15 Apr 24
Tharimmune Announces Dosing Of First Patient In Phase 1 Clinical Trial Of TH104, Its Lead Candidate For Pruritus In Primary Biliary Cholangitis
5 Feb 24
Press releases
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
23 Apr 24
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
15 Apr 24
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
5 Mar 24
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
5 Feb 24